Red Light Holland Announces Filament Health Shareholder Approval of Acquisition

• Headline: Red Light Holland Announces Filament Health Shareholder Approval of Acquisition.
• Date: April 27, 2026.
• Core Event: Filament Health shareholders voted to approve the plan of arrangement for acquisition by Red Light Holland Corp.
• Vote Results: Approximately 99.99% of votes cast were in favor (99.98% excluding related parties).
• Transaction Structure: Completion via issuance of up to 182,447,452 Red Light common shares.
• Ownership Split: Post-closing, Filament shareholders will hold approximately 30% of outstanding Red Light shares; existing Red Light shareholders retain ~70%.
• Closing Timeline: Final court order application April 28, 2026; expected closing on or about April 29, 2026.
• Consideration Details: Includes shares to settle Filament debt and transaction bonuses.
• Lock-up Provisions: Staged release of consideration shares (50% at 6 months, 25% at 9 months, 25% at 12 months).

• Expectation vs. Reality: The definitive agreement was announced on March 10, 2026, and an interim court order was obtained on March 23, 2026. Shareholder approval was a known closing condition. The 99.99% vote confirms the deal will proceed as planned without surprise opposition.
• Market Reaction: The stock price has already rallied from ~$0.01 in early March to $0.04 by late April, pricing in the successful completion of the merger. This news removes the final execution risk but does not introduce new fundamental value beyond what was agreed upon in March.
• Dilution Impact: The issuance of 182 million shares represents a significant dilution event for existing shareholders (reducing ownership to 70%). While this consolidates assets (IP, clinical pipeline), it materially increases the share count from pre-close levels (~425M estimated).
• Debt Settlement: The transaction includes settling Filament's debt via equity issuance. This cleans up the balance sheet but further dilutes existing holders rather than using cash reserves.
• Conclusion: The news is positive as it secures the strategic pivot to a clinical-stage biotech company, but it is routine in the context of the M&A timeline announced months ago.

• Overview: Red Light Holland Corp. is transitioning from a consumer functional mushroom brand to a regulated psychedelic medicine developer through the acquisition of Filament Health.
• Flagship Project: PEX010 (Filament's botanical psilocybin drug candidate). It is authorized by Health Canada and FDA for clinical trials.
• Development Status: Supplied to over 70 global research sites. Phase 1 data published April 20, 2026, showed positive outcomes for anxiety/depression in metastatic cancer patients (69% below clinical thresholds after second session).
• Operations: Maintains consumer operations via Happy Caps (Safeway partnership) and SR Wholesale (Netherlands), though focus is shifting to R&D.